Abstract
Background severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or Covid-19 is a nationwide public health emergency with significant impact on human life.
Objective To develop a new simple hematological prognostic index for Covid-19 severity state.
Patients and methods This observational cross sectional study was conducted on 250 patients with Covid-19 disease. Age, gender, and severity of Covid −19 were recorded. Complete blood count and lactate dehydrogenase were measured.
New index: COVID-19 severity-Iraqi-index = CSI index to predict COVID-19 severity.
CSI index is monocyte/lymphocyte absolute counts multiplied by LDH (lactate dehydrogenase)/upper normal reference laboratory range of LDH value.
Results Mean age of patients was 50.4 + 15.1 years. Majority of patients were Males 148 (59.2%)..Most of patients were in stage 2 and 3 (> 94%). There was a significant difference between means of White Blood Cells, lymphocytes and Monocytes among the different stages of the disease (P = 0.0001, 0.036, 0.012). There was a significant moderate correlation between the prognostic index and the stage of the disease (r=0.41, p=0.0001).
Conclusions CSI index is a new simple predictor of clinical outcome in patients with covid-19 during early stage of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethical research committee of Department of Medicine, College of Medicine, University of Baghdad with the No. ERC.DoM.CoM,UoB.Ju.2020.1 with date: of June, 2nd, 2020 and was conducted according to the Declaration of Helsinki and its amendments and the Guidelines for Good Clinical Practices issued by the Committee of Propriety Medicinal Product of the European Union. An informed consent was taken from all participants prior to their inclusion in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Yes.We agree for availability of all data referred to in the manuscript.
